Schrödinger hires ex-Eisai, Merck staff for push into clinic

Duncan Hamish Wright and W. George Lai further Schrödinger’s efforts to add translational science expertise. (Pixabay)

Schrödinger has hired researchers from Eisai and Merck to support the progress of its wholly owned assets toward the clinic. News of the hires comes weeks after Schrödinger pulled in more cash to fund its evolution into a biotech with an internal pipeline.

New York-based Schrödinger is a veteran of computer-enabled biopharma R&D, but for most of its history it has used its capabilities to support the ambitions of other companies through collaborations and the co-foundation of affiliated biotechs. Recently, Schrödinger has stepped up its internal drug discovery efforts, leading it to raise $110 million and go looking for talent that can spend the money well.

The search for new hires ended with the recruitment of Duncan Hamish Wright and W. George Lai. Wright has joined as vice president of translational science. Lai will lead Schrödinger’s translational PK/PD and drug metabolism group.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Both researchers join after long stints at larger companies. Wright spent more than 15 years at Merck, rising from the role of clinical monitor to serve as executive director for business development and licensing. The executive director role gave Wright responsibility for the scientific evaluation and execution of licensing deals and partnerships.

Lai spent more than a decade at Eisai, heading up the DMPK department for the second half of his time at the company. Prior to joining Eisai, Lai worked for about nine years at Boehringer Ingelheim.

Wright and Lai further Schrödinger’s efforts to add translational science expertise to complement its existing drug discovery capabilities. That effort saw Schrödinger hire another ex-Merck researcher, Karen Akinsanya, as chief biomedical scientist last year. Akinsanya sees the new employees benefiting Schrödinger as it heads toward clinical development.

“As our proprietary programs advance, we are expanding our translational science capabilities to ensure that we can continue to make rapid progress,” Akinsanya said in a statement. “Hamish and George have the experience and the expertise to guide our programs as we transition compounds to the clinical candidate stage.”

Suggested Articles

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.